FSMAX | IBSSX | FSMAX / IBSSX | |
Total Expense Ratio | 0.04 | 1.25 | 3% |
Annual Report Gross Expense Ratio | 0.04 | 1.37 | 3% |
Fund Existence | 14 years | 23 years | - |
Gain YTD | 13.072 | -27.284 | -48% |
Front Load | N/A | N/A | - |
Min. Initial Investment | 0 | 0 | - |
Min. Initial Investment IRA | N/A | N/A | - |
Net Assets | 41.4B | 326M | 12,699% |
Annual Yield % from dividends | 0.44 | 0.28 | 155% |
Returns for 1 year | 19.58 | -27.56 | -71% |
Returns for 3 years | 70.02 | -15.68 | -447% |
Returns for 5 years | 53.17 | -30.42 | -175% |
Returns for 10 years | 107.23 | -38.88 | -276% |
1 Day | |||
---|---|---|---|
MFs / NAME | Price $ | Chg $ | Chg % |
HLIDX | 15.65 | N/A | N/A |
Harding Loevner Intl Dev Mkts Eq Inst | |||
FPHAX | 28.62 | N/A | N/A |
Fidelity Select Pharmaceuticals Port | |||
UTMAX | 12.03 | N/A | N/A |
Victory Target Managed Allocation | |||
GSILX | 21.81 | N/A | N/A |
Goldman Sachs GQG Ptnrs Intl Opps C | |||
DLCZX | 12.27 | -0.06 | -0.49% |
Destinations Large Cap Equity Z |